242 related articles for article (PubMed ID: 16457072)
1. [Raynaud disease].
Pettersson T
Duodecim; 2005; 121(22):2411-9. PubMed ID: 16457072
[No Abstract] [Full Text] [Related]
2. Raynaud's phenomenon and celiac disease.
Gabrielli M; Candelli M; Santarelli L; Nista EC; Santoliquido A; Gasbarrini G; Pola P; Gasbarrini A
Am J Gastroenterol; 2003 Nov; 98(11):2578-9. PubMed ID: 14638377
[No Abstract] [Full Text] [Related]
3. Clues for previously undiagnosed connective tissue disease in patients with trigeminal neuralgia.
Nascimento IS; Bonfá E; de Carvalho JF; Saad CG; Vendramini MB; Teixeira MJ; Nóbrega JC; Viana VS
J Clin Rheumatol; 2010 Aug; 16(5):205-8. PubMed ID: 20661065
[TBL] [Abstract][Full Text] [Related]
4. Letter: Antinuclear antibodies-clinical significance of the nuclear immunofluorescent patterns.
Burnham TK; Bank PW
Am J Clin Pathol; 1975 Aug; 64(2):289-90. PubMed ID: 1098444
[No Abstract] [Full Text] [Related]
5. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma).
Senécal JL; Hénault J; Raymond Y
J Rheumatol; 2005 Sep; 32(9):1643-9. PubMed ID: 16142854
[No Abstract] [Full Text] [Related]
6. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases.
Poirier TJ; Rankin GB
Am J Gastroenterol; 1972 Jul; 58(1):30-44. PubMed ID: 4537959
[No Abstract] [Full Text] [Related]
7. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort.
Trapiella-Martínez L; Díaz-López JB; Caminal-Montero L; Tolosa-Vilella C; Guillén-Del Castillo A; Colunga-Argüelles D; Rubio-Rivas M; Iniesta-Arandia N; Castillo-Palma MJ; Sáez-Comet L; Egurbide-Arberas MV; Ortego-Centeno N; Freire M; Vargas-Hitos JA; Ríos-Blanco JJ; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Chamorro-Fernández AJ; Pla-Salas X; Madroñero-Vuelta AB; Ruiz-Muñóz M; Fonollosa-Pla V; Simeón-Aznar CP;
Autoimmun Rev; 2017 Aug; 16(8):796-802. PubMed ID: 28564618
[TBL] [Abstract][Full Text] [Related]
8. [RACAND syndrome: distinct entity or initial presentation of systemic scleroderma].
Smiti Khanfir M; Bellakhal S; Said F; Ben Salem T; Ben Ghorbel I; Lamloum M; Hamzaoui A; Houman MH
Tunis Med; 2015 Jun; 93(6):392. PubMed ID: 26644105
[No Abstract] [Full Text] [Related]
9. [General practice-relevant diagnostic and differential diagnostic aspects of collagen diseases. Sclerodermia progressiva, dermatomyositis and periarteritis nodosa].
Apostoloff E; Sönnichsen N
Z Arztl Fortbild (Jena); 1987; 81(8):388-91. PubMed ID: 2887075
[No Abstract] [Full Text] [Related]
10. [Stroke and scleroderma. Cerebral Raynaud?].
Montaner J; Domínguez J; Molina C; Alvarez-Sabín J
Neurologia; 2001 May; 16(5):236-7. PubMed ID: 11412726
[No Abstract] [Full Text] [Related]
11. Differential diagnosis of scleroderma and pseudoscleroderma.
Fabri M; Hunzelmann N
J Dtsch Dermatol Ges; 2007 Nov; 5(11):977-84. PubMed ID: 17976138
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Raynaud phenomenon in systemic sclerosis.
Sinnathurai P; Schrieber L
Intern Med J; 2013 May; 43(5):476-83. PubMed ID: 23347192
[TBL] [Abstract][Full Text] [Related]
13. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group.
Avouac J; Fransen J; Walker UA; Riccieri V; Smith V; Muller C; Miniati I; Tarner IH; Randone SB; Cutolo M; Allanore Y; Distler O; Valentini G; Czirjak L; Müller-Ladner U; Furst DE; Tyndall A; Matucci-Cerinic M;
Ann Rheum Dis; 2011 Mar; 70(3):476-81. PubMed ID: 21081523
[TBL] [Abstract][Full Text] [Related]
14. [Clinico-immunological characteristics of the course of systemic scleroderma].
Musaev SK; Speranskiĭ AI
Ter Arkh; 1984; 56(5):42-5. PubMed ID: 6611599
[No Abstract] [Full Text] [Related]
15. The spectrum of scleroderma.
LeRoy EC; Lomeo R
Hosp Pract (Off Ed); 1989 Oct; 24(10A):33-42 contd. PubMed ID: 2509491
[No Abstract] [Full Text] [Related]
16. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS).
Pope J
Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S98-111. PubMed ID: 22588774
[No Abstract] [Full Text] [Related]
17. [Item 327--Raynaud phenomenon].
CEDEF
Ann Dermatol Venereol; 2012 Oct; 139(11 Suppl):A223-6. PubMed ID: 23176853
[No Abstract] [Full Text] [Related]
18. [Anticentromere antibody, CREST and cancer].
Boyeldieu D; Rouquette-Gally AM; Laugier A; Abuaf N
Presse Med; 1987 Nov; 16(38):1924-5. PubMed ID: 2962150
[No Abstract] [Full Text] [Related]
19. [Diagnosis of systemic scleroderma].
Guĭda PP
Klin Med (Mosk); 1983 Jun; 61(6):82-5. PubMed ID: 6887774
[No Abstract] [Full Text] [Related]
20. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
